Clinical Management of Antipsychotic-Induced Hyperprolactinemia

Perspectives in Psychiatric Care

Volumn 52, Issue 2, 2016, Pages 145-152

  Wong Anuchit, Choochart ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF NURSING   (United States)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

Advanced psychiatric mental health nurse; Antipsychotic agent; Clinical management; Hyperprolactinemia

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN;

BLOOD; CASE MANAGEMENT; CHEMICALLY INDUCED; HUMAN; HYPERPROLACTINEMIA; MENTAL DISORDERS; NURSING; PATIENT EDUCATION; STANDARDS;

ANTIPSYCHOTIC AGENTS; CASE MANAGEMENT; HUMANS; HYPERPROLACTINEMIA; MENTAL DISORDERS; NURSING SERVICES; PATIENT EDUCATION AS TOPIC; PROLACTIN;

EID: 84924662627     PISSN: 00315990     EISSN: 17446163     Source Type: Journal    
DOI: 10.1111/ppc.12111     Document Type: Article

References (32)

1. American Psychiatric Association. (2006). American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. Compendium 2006. Arlington, VA: American Psychiatric Association.
2. Bardal, S., Waechter, J., & Martin, D. (2011). Applied pharmacology. China: Saunders, Elsevier.
3. Bargiota, S. I., Bonotis, K. S., Messinis, I. E., & Angelopoulos, N. V. (2013). The effects of antipsychotics on prolactin levels and women's menstruation. Schizophrenia Research and Treatment, 2013, 1-10. doi:10.1155/2013/502697
4. Barrowclough, C., Haddock, G., Wykes, T., Beardmore, R., Conrod, P., Craig, T., & Tarrier, N. (2010). Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trial. British Medical Journal, 341, c6325. doi:10.1136/bmj.c6325
5. Boyd, K. N., & Mailman, R. B. (2012). Dopamine receptor signaling and current and future antipsychotic drugs. Handbook of Experimental Pharmacology, 212, 53-86. doi:10.1007/978-3-642-25761-2_3
6. Bushe, C., Bradley, A., & Pendlebury, J. (2010). A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry? Annals of Clinical Biochemistry, 47, 292-300. doi:10.1258/acb.2010.010025
7. Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., & Giustina, A. (2006). Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology, 65, 265-273. doi:10.1111/j.1365-2265.2006.02562.x
8. Citrome, L. (2008). Current guidelines and their recommendations for prolactin monitoring in psychosis. Journal of Psychopharmacology (Oxford, England), 22(2 Suppl.), 90-97. doi:10.1177/0269881107087373
9. Fitzgerald, P., & Dinan, T. G. (2008). Prolactin and dopamine: What is the connection? A review article. Journal of Psychopharmacology (Oxford, England), 22(2 Suppl.), 12-19. doi:10.1177/0269216307087148
10. Fung, K. M., Tsang, H. W., & Cheung, W.-M. (2011). Randomized controlled trial of the self-stigma reduction program among individuals with schizophrenia. Psychiatry Research, 189, 208-214. doi:10.1016/j.psychres.2011.02.013
11. Haddad, P. M., & Wieck, A. (2004). Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs, 64, 2291-2314. doi:10.2165/00003495-200464200-00003
12. Holt, R. I., & Peveler, R. C. (2011). Antipsychotics and hyperprolactinaemia: Mechanisms, consequences and management. Clinical Endocrinology, 74, 141-147. doi:10.1111/j.1365-2265.2010.03814.x
13. Inder, W. J., & Castle, D. (2011). Antipsychotic-induced hyperprolactinaemia. Australian and New Zealand Journal of Psychiatry, 45, 830-837. doi:10.3109/00048674.2011.589044
14. Jones, A., & Jones, M. (2008). Managing patients with antipsychotic drug-induced hyperprolactinaemia. Nursing Standard, 23(6), 48-55. doi:10.7748/ns2008.10.23.6.48.c6709
15. Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet, 373, 31-41. doi:10.1016/s0140-6736(08)61764-x
16. Madhusoodanan, S., Parida, S., & Jimene, C. (2010). Hyperprolactinemia associated with psychotropic-A review. Human Psychopharmacology: Clinical and Experimental, 25, 281-297. doi:10.1002/hup.1116
17. Mancini, T., Casanueva, F. F., & Giustina, A. (2008). Hyperprolactinemia and prolactinomas. Endocrinology and Metabolism Clinics of North America, 37, 67-99. doi:10.1016/j.ecl.2007.10.013
18. Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. (2011). Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 96, 273-288. doi:10.1210/jc.2010-1692
19. Milano, W., D'Acunto, C. W., De Rosa, M., Festa, M., Milano, L., Petrella, C., & Capasso, A. (2011). Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Reviews on Recent Clinical Trials, 6, 52-63. doi:10.2174/157488711793980138
20. Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine, 42, 125-147. doi:10.1017/s003329171100105x
21. Molitch, M. E. (2008). Drugs and prolactin. Pituitary, 11, 209-218. doi:10.1007/s11102-008-0106-6
22. Perez, S. M., & Lodge, D. J. (2014). New approaches to the management of schizophrenia: Focus on aberrant hippocampal drive of dopamine pathways. Drug Design, Development and Therapy, 8, 887-896. doi:10.2147/dddt.s42708
23. Redding, C. A., Rossi, J. S., Rossi, S. R., Velicer, W. F., & Prochaska, J. O. (2000). Health behavior models. International Electronic Journal of Health Education, 3, 180-193.
24. Schlechte, J., Dolan, K., Sherman, B., Chapler, F., & Luciano, A. (1989). The natural history of untreated hyperprolactinemia: A prospective analysis. Journal of Clinical Endocrinology and Metabolism, 68, 412-418. doi:10.1210/jcem-68-2-412
25. Seeman, M. V. (2009). Secondary effects of antipsychotics: Women at greater risk than men. Schizophrenia Bulletin, 35, 937-948. doi:10.1093/schbul/sbn023
26. Serri, O., Chik, C. L., Ur, E., & Ezzat, S. (2003). Diagnosis and management of hyperprolactinemia. Canadian Medical Association Journal, 169, 575-581.
27. Taylor, D., Paton, C., & Kapur, S. (2012). Prescribing guidelines in psychiatry (11th ed.). CornWall, UK: A John Wiley & Sons.
28. Thompson, D. R., Chair, S. Y., Chan, S. W., Astin, F., Davidson, P. M., & Ski, C. F. (2011). Motivational interviewing: A useful approach to improving cardiovascular health? Journal of Clinical Nursing, 20, 1236-1244. doi:10.1111/j.1365-2702.2010.03558.x
29. Torre, D. L., & Falorni, A. (2007). Pharmacological causes of hyperprolactinemia. Therapeutics and Clinical Risk Management, 3, 929-951.
30. Tsang, H. W. H. (2013). Stages of change, self-stigma, and treatment compliance among Chinese adults with severe mental illness. Hong Kong Medical Journal, 19(9 Suppl.), 4-8.
31. Turrone, P., Kapur, S., Seeman, M. V., & Flint, A. J. (2002). Elevation of prolactin levels by atypical antipsychotics. American Journal of Psychiatry, 159, 133-135. doi:10.1176/appi.ajp.159.1.133
32. Zhu, L. X., Ho, S. C., Sit, J. W., & He, H. G. (2014). The effects of a transtheoretical model-based exercise stage-matched intervention on exercise behavior in patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling, 95, 384-392. doi:10.1016/j.pec.2014.03.013